Plain-English translation of NCT05133882 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called Crifortinib Besylate to see if it works better when combined with standard chemotherapy drugs (either a two-drug combination or a single drug called azacitidine) for adults who have just been diagnosed with acute myeloid leukemia (AML), a serious blood cancer. The study will look at different dose levels of the medication to find the safest and most effective amount, and measure how well the treatment combination works overall.
Acute myeloid leukemia is a serious blood cancer that is difficult to treat, and doctors are looking for new ways to improve survival and outcomes for newly diagnosed patients. This medication targets a specific change in cancer cells that many AML patients have, and researchers believe combining it with standard chemotherapy might be more effective than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
You would take the new medication by mouth on specific days of each treatment cycle, alongside chemotherapy drugs given by infusion or injection. The study involves multiple clinic visits for blood tests, examinations, and monitoring of how well you're tolerating the treatment. Treatment cycles typically last several weeks, and you would continue for as long as the treatment is working and you are not experiencing unacceptable side effects. Researchers will carefully watch you for any safety concerns and adjust the medication dose if needed.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Sunshine Lake Pharma Co., Ltd.
Enrollment target
~133 participants
Started
October 2022
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jie Jin, Doctor
First Affiliated Hospital of Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.